

COLUMBIA UNIVERSITY  
IN THE CITY OF NEW YORK

ENVIRONMENTAL HEALTH & SAFETY

Br. 2

RECEIVED  
REGION I  
2011 OCT 13 AM 8:16

October 7, 2011

U.S. Nuclear Regulatory Commission

Division of Nuclear Materials Safety

Region I

King of Prussia, Pennsylvania 19406

03034376


Attention: Thomas K. Thompson RE: License: 31-28713-01

Dear Mr. Thompson:

I would like to inform you that Dr. David Brenner has stepped down from the chairmanship of the Radiation Safety Committee and was replaced by Dr. Chaitanya R. Divgi, MD whose CV is attached to this letter.

Thank you for your assistance in making the proper changes.

Sincerely,



George Hamawy

Radiation Safety Officer for Research

Cc: Dr. C. Divgi

Dr. T. Morgan

C. Crowley

## Curriculum Vitae

### Chaitanya R. Divgi, MD

#### Education:



MBBS	Bangalore University, Bangalore, India (Medicine)
MS	New York University (Health Management)
MD	State University of New York, NY (Medicine)

#### Postgraduate Training and Fellowship Appointments:

1975-1976	Rotating Intern, St. Martha's Hospital and St. John's Medical College, Bangalore, India
1977	Resident, Internal Medicine and Nuclear Medicine, Jaslok Hospital and Research Centre, Bombay, India
1977-1978	Clinical Graduate Student, Nuclear Medicine, Radiation Medicine Centre, Bombay, India
1978	Registrar, Internal Medicine and Nuclear Medicine, Jaslok Hospital and Research Centre, Bombay, India
1978-1980	Senior Registrar, Internal Medicine and Nuclear Medicine, Jaslok Hospital and Research Centre, Bombay, India
1980-1981	Special Fellow, Internal Medicine and Nuclear Medicine, Jaslok Hospital and Research Centre, Bombay, India
1985-1987	Resident, Nuclear Medicine, Memorial-Sloan Kettering Cancer Center, New York, NY
1987-1991	Fellow, Nuclear Immunology, Memorial-Sloan Kettering Cancer Center, New York, NY
1987-1988	Fellow, Clinical Immunology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

#### Licensure:

1988-Present	State of New York Lic#185493-1
2006-Present	State of Pennsylvania Lic#MD429114

#### Specialty Certification:

1988	American Board of Nuclear Medicine
1998	American College of Nuclear Cardiology
1981	Diplomate, Internal Medicine, National Board of Medicine, New Delhi, India, January 1981.
1979	Diploma in Radiation Medicine (DRM), Bombay University, Bombay, India, March 1979 (Distinction)

#### Military Service:

None

Professional Organizations and Societies:

Society of Nuclear Medicine  
 Nuclear Oncology Council (President)  
 American Association of Cancer Research  
 American College of Nuclear Physicians  
 Indian Society of Nuclear Medicine  
 American Society of Clinical Oncology  
 American Society of Nuclear Cardiology  
 Association of Physicians of India  
 Association of University Radiologists  
 United Arab Emirates Cancer Registry

Academic Appointments:

1991-1996	Assistant Professor, Cornell University Medical College, New York, NY
1996-2002	Associate Professor, Cornell University Medical College, New York, NY
2002-2006	Professor, Weill Medical College of Cornell University, New York, NY
2006-2011	Professor of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA
2006-2011	Professor of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA (Secondary)
2006-2011	Professor, Wistar Institute, Philadelphia, PA
2011-	Professor of Clinical Radiology, College of Physicians and Surgeons of Columbia University, NY
2011-	Vice Chairman / Research, Department of Radiology, College of Physicians and Surgeons of Columbia University, NY
2011	Director, Columbia University Medical Center PET Center

Hospital Appointments:

1981-1982	Chief of Nuclear Medicine, Choithram Hospital and Research Centre, Indore, India
1982-1985	Specialist Physician and Head, Nuclear Medicine Service, Department of Medical Imaging, Al-Jazeera Hospital, Ministry of Health, Abu Dhabi, United Arab Emirates
1991-1996	Assistant Member and Assistant Attending Physician, Department of Radiology, Nuclear Medicine Service and Department of Medicine, Clinical Immunology Service, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY
1992-2001	Head, Monoclonal Antibody Unit, Nuclear Medicine Service, MSKCC, New York, NY
1993-2001	Head, Nuclear Cardiology Section, Nuclear Medicine Service, MSKCC, New York, NY

1994-2006	Director, Nuclear Medicine Outpatient Consultation and Therapy Clinic, Nuclear Medicine Service, MSKCC, New York, NY
1996-2002	Associate Attending Physician and Associate ,Department of Radiology and Department of Medicine, MSKCC, New York, NY
2002-2006	Attending Physician and Member, Nuclear Medicine and Clinical Immunology Services, Department of Radiology and Department of Medicine, MSKCC, New York, NY
2002-2006	Head, Targeted Therapy Section, Nuclear Medicine Service, MSKCC, New York, NY
2006-2011	Division Chief, Nuclear Medicine & Clinical Molecular Imaging, Department of Radiology, Hospital of the University of Pennsylvania
2011-	Attending Physician, Department of Radiology, Columbia University Medical Center

Honors

1995	Member, Sub-committee on human use, Committee on Radiation
1995-2004	Lectureship, Institute for Molecular & Immunologic Medicine, Barcelona, Spain
1997	Lectureship, Royal College of Radiologists at the University of Hong Kong, Hong Kong
1999-2003	Lectureship, University of Singapore, Singapore
2000-2003	Lectureship, Tata Institute for Fundamental Research, Bombay, India
2000	Lectureship, Royal College of Physicians of Canada
2001-Present	Member, Clinical Oncology Study Section, Center for Scientific Review, National Cancer Institute, National Institutes of Health
2003	Vikram Sarabhai Memorial Oration Award, SNM (India)
2004	Keynote Speaker: First International Symposium on Nuclear Oncology, Brazil
2004	Nuclear Oncology update, Radiologic Society of North America Annual Meeting.
2004	Keynote address, Society of Nuclear Medicine (India) annual meeting
2005	Keynote Speaker: First International Symposium on Radiopharmaceutical Therapy, Cyprus.

Lectures by Invitation:

2000	Nuclear Oncology: The New Millennium at the Canadian Society of Nuclear Medicine
2000	Medical Oncology: PET in Oncology: Nuclear Medicine Therapy in Oncology at the University of Alberta Cross Cancer Centre
2000	2000, 2001, 2004 Lectureship at Tata Memorial Hospital and Cancer Research Centre, Bombay, India.
2001	Immunotherapy of Renal Carcinoma at the University of Nijmegen
2002	Design of Phase I and II Clinical Trials at the Society of Nuclear Medicine Midwinter Symposium

- 2003 Vikram Sarabhai Memorial Oration Award, SNM (India)
- 2004 Nuclear Oncology update, Radiologic Society of North America Annual Meeting
- 2004 Keynote Speaker: First International Symposium on Nuclear Oncology, Brazil
- 2005 Keynote Speaker: First International Symposium on Radiopharmaceutical Therapy, Cyprus.
- 2007 Nuclear Cardiology: PET Assessment of Cardiac Function at the American Pharmacists Association (APhA) Annual Meeting & Exposition, Atlanta, Georgia USA
- 2007 Surgery, Radiation and Imaging in the Management of Melanoma at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois
- 2007 NCI Network for Translational Research in Optical Imaging, Philadelphia, Pennsylvania USA
- 2007 5th International Workshop on Nuclear Oncology (iwNO), Budapest, Hungary
- 2007 7th World Basic Urological Research Congress, Dublin, Ireland
- 2007 Philadelphia Roentgen Ray Society, Philadelphia, Pennsylvania USA
- 2008 Advances in Molecular Imaging for Radiation Oncology - ASTRO Annual Meeting, Boston, MA
- 2008 PET/CT in cancer clinical research, and overview on trial design (ACOSOG) Annual Meeting, Chicago, IL
- 2008 "Overview to Study Design" SNM 55th Annual Meeting, New Orleans, LA
- 2008 Molecular Imaging & Cancer - Optimizing Clinical Trails & Clinical Practice-Imaging View, (ASCO)Annual Meeting- Chicago, IL
- 2008 Genotype to Phenotype to Targeted Therapy - John Hopkins, Balitmore, MD
- 2009 Nuclear Oncologic Therapy: 1. Thyroid cancer 2. Bone pain palliation 3. Radioimmunotherapy - King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
- 2009 Molecular Imaging: Revolutionizing Modern Medicine- SNM Annual Meeting, Toronto, Canada
- 2009 Radioimmunotherapy: An option for Managing Non-Hodgkin's Lymphoma-Pennsylvania Hospital
- 2009 Radiopharmaceutical Therapy: Esoteric to Mainstream Practice - Facing the Challenges, SNM Mid-Winter Symposium-Clearwater, FL
- 2009 Radioligands in Melanoma Diagnosis & Therapy - Tenth Annual Wallace H. Clark Jr., MD Lectureship
- 2009 Towards re-definition of molecular imaging & radiotherapy in Radiation Oncology: Biello Lecture-Washington Univeristy, ST Louis, MO

- 2010 Genitourinary Cancers Symposium,; Molecular Imaging for Phenotypic Characterization of Urologic Cancers: Implication for Management and Targeted Therapy (G250 PET), San Francisco, CA
- 2010 Bayhealth Oncology Symposium: "Frontier in cancer imaging: the search for imaging biomarkers", Dover, DE
- 2010 World Conference on Interventional Oncology: Neuroendocrine Tumors & Cholangiocarcinoma: Molecularly Targeted Radiotherapy for Metastatic NET". Lowes Hotel, Philadelphia, PA
- 2010 Ninth International Congress on Targeted Therapies in Cancer - Lecture: "Imaging of Tumor Response", Washington, DC
- 2010 New England Chapter of the SNM: "Clinical Applications of TOF-PET" in the field of Oncology and other applications/Apoptosis Imaging Current Status, Role in Medical Management and future prospects.

Grants:Current:

Cutting Off Fuel Supply: A New Approach To The Treatment Of Pancreatic Cancer, American Association For Cancer Research, SU2C-AACR-DT0509, 10/2009-9/2012 (Craig B. Thompson, PI), \$5,565,150/annual direct costs (Role in grant: Co-PI)

Functional Characterization Of Oprm1 A118g In Nicotine Dependence, National Institute On Drug Abuse/Nih/Dhhs, 3-R21-DA-027066-02S1, 9/2009-8/2011 (Caryn Lerman, PI), \$362,907/annual direct costs (Role in grant: Co-PI)

Interaction Of Anti-Angiogenic And Cytotoxic Therapies In Colorectal Cancer, National Cancer Institute/Nih/Dhhs, 5-R01-CA-139003-02, 8/2009-7/2011 (Peter O'Dwyer, PI), \$0/annual direct costs (Role in grant: Co-PI)

American College Of Surgeons Oncology Group, Duke University, SUB TO U10-CA-076001, 12/2007-11/2010 (Chaitanya R Divgi, PI), \$7,238/annual direct costs (Role in grant: PI)

Transformative Personalized Vascular Disrupting Cancer Immunotherapy, 1-R01-CA156695, National Cancer Institute/NIH/DHHS, 9/2010 – 8/2015 (George Coukos, PI) \$635,042 Total funding (Role in project: co-PI)

A Phase I-II Study Evaluating The Maximum Tolerated Dose, Safety, And Efficacy Of Ultratrace Iobenguane I 131 In Patients With Malignant Pheochromocytoma/Paraganglioma, Molecular Insight Pharmaceuticals, Inc., MIP-IB12, 4/2009-2/2013 (Daniel A Pryma, PI), \$180,300/annual direct costs (Role in grant: Co-PI)

Targeting Glioblastoma Through Tem-1, Ben And Catherine Ivy Foundation, N/A, 1/2009-12/2010 (George Coukos, PI), \$358,978/annual direct costs (Role in grant: Co-PI)

The Ludwig Institute For Cancer Research (LICR) Affiliate Program, Ludwig Institute For Cancer Research, 7/2008-6/2011 (Chaitanya R Divgi, PI), \$170,000/annual direct costs (Role in grant: PI)

Past 3 years:

Cyclotron For Biomedical Research, National Institutes Of Health, 1-S10-RR-025076-01 (REVIS, 7/2008-6/2010 (Chaitanya R Divgi, PI), \$2,000,000/annual direct costs (Role in grant: PI)

Determination Of Optimal Radiometal-Chelator Complexes For Pet-Ct Visualization Of Le-Y Tumors Using Hu3s193, Radiological Society Of North America, RMS0818, 7/2008-9/2008 (James Walter, PI), \$3,000/annual direct costs (Role in grant: Co-PI)

Utility Of [F-18] Fluorodopa For Neonatal Hyperinsulinism: A Phase II, Food And Drug Administration, 1-R01-FD-003457-01, 12/2007-11/2009 (Chaitanya R Divgi, PI), \$205,080/annual direct costs (Role in grant: PI)

Departmental and University Committees:

1991-1997	Member and Nuclear Medicine Physician Representative, Department of Radiology Quality Assurance Committee, Memorial Sloan-Kettering Institute
1995-2006	Member, Committee on Radiation, Sloan-Kettering Institute
1995-2006	Member, Sub-committee on Human Use, Committee on Radiation
2003-2006	Member, Advisory Board, Office of Clinical Research, Memorial Sloan-Kettering Institute
2003-2006	Experimental Therapeutics Committee, Memorial Sloan-Kettering Institute
2003-2006	Molecular Pharmacology Committee, Memorial Sloan-Kettering Cancer Center
2004-2006	Member, Investigational New Drug Committee, Memorial Sloan-Kettering Cancer Center
2006-2011	Member, Executive Committee, Department of Radiology, University of Pennsylvania School of Medicine
2006-2011	Member, Committee on Appointments and Promotions, Department of Radiology, University of Pennsylvania School of Medicine
2007-2011	Member, Radioactive Drug Research Committee, University of Pennsylvania School of Medicine
2009-2011	Member, Clinical Trials Scientific Review and Monitoring Committee, Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine
2008-2011	Member, Faculty Advisory Committee, Office of Human Research, University of Pennsylvania School of Medicine

Editorial Positions:

1993-1998	Associate Editor, Journal of Nuclear Medicine
1999-Present	Associate Editor, Clinical Nuclear Medicine.
2002-Present	Associate Editor, World Journal of Nuclear Medicine and Molecular Imaging.

Consultative Positions:

2007-Present	Cancer Steering Committee, The Biomarker Consortium, Foundation for the National Institute of Health
2007-2009	Advisory Board, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2006-Present	Advisory Board, Nanoscan Imaging, LLC
2004-Present	Consultant/Advisor, Wilex AG
2001-2006	Scientific Advisor, Biocon Ltd

Original, Peer reviewed Articles:

1. Lele RD, **Divgi CR**, Bhonsle US. Comparison of sublingual nitroglycerine and isosorbide dinitrate ointment by radionuclide ventriculography. **J Assoc Physicians India** 1981; 29:447-456.
2. **Divgi CR**, Lisann NM, Yeh SDJ, Benua RS. Technetium-99m albumin scintigraphy in the diagnosis of protein-losing enteropathy. **J Nucl Med** 1986; 27:1710-1712.
3. Goldenberg A, Masui H, **Divgi CR**, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. **J Natl Cancer Inst** 1989; 81:1616-1625.
4. Rivoire M, Yoshida K, **Divgi CR**, Welt S, Cohen AM, Sigurdson ER. Radioimmunodetection of hepatic metastases from human colon cancer in nude mice with a gamma-detecting probe. **Cancer Res** 1990; 50:877s-879s.
5. Yoshida K, Rivoire M, **Divgi CR**, Welt S, Cohen AM, Sigurdson ER. Radiolocalization of monoclonal antibodies in hepatic metastases from human colon cancer in congenitally athymic mice. **Cancer Res** 1990; 50:862s-865s.
6. Welt S, **Divgi CR**, Real FX, Yeh S, Sakamoto J, Cohen A, Sigurdson ER, Kemeny N, Oettgen HF, Old LJ. Quantitative analysis of antibody localization in human metastatic colon cancer: a Phase I study of monoclonal antibody A33. **J Clin Oncol** 1990; 8:1894-1906.
7. Scheinberg DA, Strauss DJ, Yeh SD, **Divgi CR**, Garin Chesa P, Graham M, Pentlow K, Coit D, Oettgen HF, Old LJ. A Phase I toxicity, pharmacology, imaging and dosimetry trial of <sup>131</sup>I-labeled monoclonal antibody OKB7 in patients with B cell lymphoma. **J Clin Oncol** 1990; 8:792-803.

8. Rivoire M, Yodhida K, **Divgi CR**, Niedzwiecki D, Chapman D, Sigurdson E. Intraportal injection of specific monoclonal antibody in nude mice with liver metastasis. **Chirurgie** 1990; 116:721-729.
9. **Divgi CR**, Cohen AM. Radioimmunolocation of metastases from adenocarcinoma of the colon: using a hepatoma antibody. **Hepatology**. 1990; 11: 891-892.
10. **Divgi CR**, Welt S, Kris MG, Real FX, Yeh SD, Gralla RJ, Merchant B, Schweighart S, Unger M, Larson SM, Mendelsohn J.. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. **J Natl Cancer Inst** 1991; 83:97-104.
11. Scheinberg DA, Lovett D, **Divgi CR**, Graham MC, Berman E, Pentlow K, Feirt N, Finn R, Clarkson BD, Gee TS, Larson SM, Oettgen HF, Old LJ. Phase I trial of monoclonal antibody M195 in AML: specific bone marrow targeting and internalization of radionuclide. **J Clin Oncol** 1991; 9:478-490.
12. **Divgi CR**, McDermott K, Johnson D, Schnobrich KE, Finn RD, Cohen AM, Larson SM. Detection of hepatic metastases from colorectal carcinoma using <sup>111</sup>In-labeled monoclonal antibody C110. **Nucl Med Biol** 1991; 18:705-710.
13. **Divgi CR**, Czuczman M, Straus DJ, Lovett D, Garin-Chesa P, Yeh SD, Graham MC, Pentlow K, Finn RD, Gee TS. Pharmacology, Dosimetry, Toxicity, Imaging, and therapeutic effects of 131I-labeled monoclonal antibody (MAB) in acute myelogenous leukemia (AML) and lymphoma. **Antibody Immunoconj Radiopharm** 1991; 4:203.
14. Scheinberg DA, Lovett D, **Divgi CR**, Graham MC, Berman E, Pentlow K, Feirt N, Finn R, Clarkson BD, Gee TS, Larson SM, Oettgen HF, Old LJ. A phase I trial of monoclonal antibody M195 in AML: specific bone marrow targeting and internalization of radionuclide. **J Clin Oncol** 1991; 9:478-490.
15. Yoshida K, Riviore ML, **Divgi CR**, Niedzwiecki D, Cohen AM, Sigurdson ER. Effect of tumor size on monoclonal antibody uptake in a metastatic model. **J Surg Oncol** 1992, 49:249-252.
16. Oosterwijk E, Bander NH, **Divgi CR**, Welt S, Wakka JC, Finn RD, Carswell EA, Larson SM, Warnaar SO, Fleuren GJ, Oettgen HF, Old LJ. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. **J Clin Oncol** 1993, 11:738-750.
17. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, **Divgi CR**, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM, Scheinberg DA. Dose-escalation trial of

- M195 labeled with iodine 131 for cytoablation and marrow ablation in relapsed or refractory myeloid leukemias. **J Clin Oncol** 1993; 11:294-303.
18. Sgouros G, Graham MC, **Divgi CR**, Larson SM, Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. **J Nucl Med** 1993; 34:422-430.
  19. Schneider JA, **Divgi CR**, Scott AM, Macapinlac HA, Sonenberg M, Goldsmith SJ, and Larson SM. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. **Clin Nucl Med** 1993; 18:751-753.
  20. Rubin SC, Kostakoglu L, **Divgi CR**, Federici MG, Finstad CL, Lloyd KO, Larson SM and Hoskins WJ. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX 35 in patients with epithelial ovarian cancer. **Gyn Oncol** 1993; 51:61-66.
  21. **Divgi CR**, McDermott K, Griffin TW, Johnson, DK, Schnobrich KE, Fallone PS, Scott AM, Hilton S, Cohen AM, and Larson SM. Lesion-by-lesion comparison of computerized tomography and Indium-111-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial. **J Nucl Med** 1993; 34:1656-1661.
  22. Czuczman MS, Straus DJ, **Divgi CR**, Graham M, Garin-chesa P, Finn R, Myers J, Old LJ, Larson SM, Scheinberg DA. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. **J Clin Oncol** 1993; 11:2021-2029.
  23. Rivoire ML, Yoshida K, Voiglio EJ, **Divgi CR**, Niedzwiecki D, Chapman D, Cohen AM, Sigurdson ER. Intraportal injection of monoclonal antibody in nude mice bearing hepatic metastases. **J Surg Oncol** 1993; 54(2): 71-77.
  24. \*Larson SM, Macapinlac H, Scott A, **Divgi CR**. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. **ACTA Oncologica** 1993; 32(7): 709-715.
  25. **Divgi CR**, Scott AM, McDermott K, Fallone PS, Hilton S, Siler K, Carmichael N, Daghighian F, Finn RD, Cohen AM, Schlom J, Larson SM. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. **Nucl Med Biol** 1994; 21:9-15.
  26. Caron PC, Jurcic JG, Scott AM, Finn RD, **Divgi CR**, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, Larson SM, Scheinberg DA. A Phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. **Blood** 1994; 83:1760-1768.

27. Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, **Divgi CR**, Larson SM, Scheinberg DA. Murine and humanized constructs of monoclonal antibody M195 (anti CD33) for the therapy of acute myelogenous leukemia. **Cancer** 1994; 73(suppl): 1049-1056.
28. Welt S, **Divgi CR**, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, Larson SM, Old LJ, Rettig WJ. Antibody targeting in metastatic colon cancer: A Phase I study of monoclonal antibody F19 against a cell surface protein of reactive tumor stromal fibroblasts. **J Clin Oncol** 1994; 12:1193-1203.
29. Macapinlac HA, Scott AM, Larson SM, **Divgi CR**, Yeh SDJ, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. **Nucl Med Biol** 1994; 21:731-738.
30. Kostakoglu L, **Divgi CR**, Hilton S, Cordon-Cardo C, Scott AM, Kalaigian H, Finn RD, Schlom J, Larson SM. Pre-selection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. **Cancer Invest** 1994; 12:551-558.
31. Welt S, **Divgi CR**, Kemeny N, Finn R, Scott A, Graham M, St. Germain J, Richards EC, Larson SM, Oettgen HF, Old LJ. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. **J Clin Oncol** 1994; 12: 1561-1571.
32. Schneider JA, **Divgi CR**, Scott AM, Macapinlac H, Seidman A, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following taxol chemotherapy for metastatic breast cancer. **J Nucl Med** 1994; 35: 1748-1752.
33. Scott AM, Macapinlac H, **Divgi CR**, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Melian E, Sgouros G, Pelizari C, Chen G, Goldsmith SJ, Larson SM. Clinical validation of SPECT and CT/MRI registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. **J Nucl Med** 1994; 35:1976-1984.
34. O'Boyle KP, Mattes MJ, Sigurdson ER, Sutanto-Ward E, **Divgi CR**, Welt S, Wright KE. Localization of complement fixing cytotoxic monoclonal antibodies to subcutaneous tumors and liver metastases in a syngenic immunocompetent rat colon carcinoma model. **J Immunother Emphasis Tumor Immunol** 1994; 15:175-184.
35. Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, **Divgi CR**, Larson SM, Scheinberg DA. Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. **Cancer** 1994; 73:1049-1056.
36. Schneider JA, **Divgi CR**, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, Larson SM. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. **J Nucl Med** 1994; 35: 1748-1752.

37. Scott AM, Rosa E, Mehta BM, **Divgi CR**, Finn RD, Biedler JL, Tsuruo T, Kalaigian H, Larson SM. In vivo imaging and specific targeting of P-Glycoprotein expression in multidrug resistant nude mice xenografts with I-125 MRK-16 monoclonal antibody. **Nucl Med Biol** 1995; 22: 497-504.
38. **Divgi CR**, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen D, Kostakoglu L, Schlom J, Larson SM. Phase I radioimmunotherapy trial with I-131 CC49 in metastatic colon carcinoma. **J Nucl Med** 1995; 36:586-592.
39. Kostakoglu L, Panicek DM, **Divgi CR**, Botet J, Healy J, Larson SM, Abdel-Dayem HM. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft-tissue sarcomas. **Eur J Nucl Med** 1995; 22:1232-1237.
40. **Divgi CR**, Scott AM, Gulec S, Broussard EK, Levy N, Young C, Capitelli P, Daghighian F, Williams JM, Finn RD, Kemeny N, Hilton S, Kelson D, Milenic D, Lora ME, Schlom J, Larson SM. Pilot radioimmunotherapy trial with I-131 murine monoclonal antibody (MAB) CC49 and deoxyspergualin (DSG) in metastatic colon carcinoma. **Clin Can Res** 1995; 1:1503-1510.
41. Welt S, Scott AM, **Divgi CR**, Kemeny NE, Daghighian F, Finn RD, Larson SM, Old LJ. Radioimmunotherapy of colon cancer with monoclonal antibody A33. **Tumor Targeting** 1995; 1:299-300.
42. Scott AM, Rosa E, Mehta BH, **Divgi CR**, Finn FD, Biedler JL, Kalaigian H, Larson SM. In vivo imaging and specific targeting of P-Glycoprotein expression in multidrug resistant nude mice xenografts with I-125 MRK-16 monoclonal antibody. **Nucl Med Biol** 1995; 22: 497-504.
43. Scott AM, Larson SM, **Divgi CR**, Welt S. Radioimmunodetection of colorectal cancer. **Diagn Oncol** 1995; 4:115-122.
44. Kostakoglu L, Panicek DM, **Divgi CR**, Botet J, Healey J, Larson SM, Abdel-Dayem HM. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. **Eur J Nucl Med**. 1995; 22: 1232-1237.
45. Welt S, Scott AM, **Divgi CR**, Kemeny NE, Finn RD, Daghighian F, St. Germain J, Richards EC, Larson SM, Old LJ. Phase I/II study of iodine-125 labeled monoclonal antibody A33 in patients with advanced colon cancer. **J Clin Oncol** 1996; 14:1787-1797.
46. Finstad CL, Lloyd KO, Federici MG, **Divgi CR**, Venkatraman E, Barakat RR, Finn RD, Larson SM, Hoskins WJ, Humm JL. Distribution of Radiolabeled Monoclonal Antibody MX35 F(ab')<sub>2</sub> in Tissue Samples by Storage Phosphor Screen Image

Analysis: Evaluation of Antibody Localization to Micrometastatic Disease in Epithelial Ovarian cancer. **Clin. Cancer Res** 1997; 3:1433-1442.

47. \* El-Shirbiny AM, Stavrou SS, Dnistrian A, Sonenberg M, Larson SM, **Divgi CR**. Jod-Basedow Syndrome Following Oral Iodine and Radioiodinated-Antibody Administration. **J Nucl Med** 1997; 38:1816-1817.
48. Larson SM, El-Shirbiny AM, **Divgi CR**, Sgouros G, Finn RD, Tschmelitsch J, Picon A, Whitlow M, Schlom J, Zhang J, Cohen AM. Single chain antigen binding protein (sFv CC49) first human studies in colorectal carcinoma metastatic to liver. **Cancer** 1997; 80: 2458-2468.
49. Slovin SF, Scher HI, **Divgi CR**, Reuter V, Sgouros G, Moore M, Weingard K, Pettengall R, Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D, Dnistrian A, Shapiro L, Schlom J, Larson SM. Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. **Clin Cancer Res** 1998; 4: 643-651.
50. Barendswaard EC, Scott AM, **Divgi CR**, Williams C Jr, Coplan K, Riedel E, Yao TJ, Gansow OA, Finn RD, Larson SM, Old LJ, Welt S Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. **Int J Oncol**. 1998; 12: 45-53.
51. \*Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, Larson SM, Old LJ, **Divgi CR**. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients. **J Nucl Med** 1998; 39: 484-489.
52. **C.R. Divgi**, N.H. Bander, A.M. Scott, J.A. O'Donoghue, G. Sgouros, S. Welt, R.D. Finn, F. Morrissey, P. Capitelli, J.M. Williams, D. Deland, A. Nakhre, E. Oosterwijk, S. Gulec, M.C. Graham, S.M. Larson, L.J. Old. Phase I/II Radioimmunotherapy Trial With Iodine-131 Labeled Monoclonal Antibody (Mab) G250 In Metastatic Renal Cell Carcinoma. **Clin Cancer Res** 1998; 4: 2729-2739.
53. J.A. O'Donoghue, G. Sgouros, **C.R. Divgi**, J.L. Humm. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry. **J Nucl Med** 2000; 41: 538-547.
54. \*Akhurst T, Ng V V, Larson SM, O'Donoghue JA, O'Neel J, Erdi Y, **Divgi CR**. Tumor Burden Assessment with Positron Emission Tomography with [18-F] 2-fluoro 2-deoxyglucose (FDG PET) Modeled in Metastatic Renal Cell Cancer. **Clin Positron Imaging**. 2000; 3: 57-65.
55. Tanswell P, Garin-Chesa P, Rettig WJ, Welt S, **Divgi CR**, Casper ES, Finn RD, Larson SM, Old LJ, Scott AM. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. **Br J Clin Pharmacol**. 2001; 51: 177-180.

56. Sundram FX, Jeong J-M, Zanzonico P, Bernal P, Chau T, Onkhuudai P, **Divgi C**, Knapp FF (Russ) Jr., Buscombe J, Padhy AK. Trans-arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma-An IAEA sponsored multi-centre phase 1 study. **W Jour Nucl Med** 2002; 1: 1-13.
57. Robbins RJ, Larson SM, Sinha N, Shaha A, **Divgi CR**, Pentlow KS, Ghossein R, Tuttle RM. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. **J Nucl Med.** 2002; 43: 1482-1488.
58. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, **Divgi CR**, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. **Blood.** 2002; 100: 1233-1239.
59. O'Donoghue JA, Baidoo N, Deland D, Welt S, **Divgi CR**, Sgouros G. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy. **Cancer Biother Radiopharm.** 2002; 17: 435-443.
60. Burke JM, Caron PC, Papadopoulos EB, **Divgi CR**, Sgouros G, Panageas KS, Finn RD, Larson SM, O'Reilly RJ, Scheinberg DA, Jurcic JG. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. **Bone Marrow Transplant.** 2003; 32: 549-556.
61. \* Pandit-Taskar N, Hamlin PA, Reyes S, Larson SM, **Divgi CR**. New strategies in radioimmunotherapy for lymphoma. **Curr Oncol Rep.** 2003; 5: 364-371.
62. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, **Divgi CR**, Hanson LH, Mitchell P, Gansen DN, Larson SM, Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L, Amelsberg A, Vlock D, Rettig WJ, Old LJ. A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. **Clin Cancer Res.** 2003; 9: 1639-1647.
63. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, **Divgi CR**, Larson SM, Zelenetz AD. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. **J Nucl. Med.** 2003; 44: 260-8.
64. \***Divgi CR**, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, Larson SM, Old LJ. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. **J Nucl Med.** 2004; 45: 1412-1421.

65. \* Kaufman HL, **Divgi CR**. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination. **Clin Cancer Res** 2005; 11: 6757-6762.
66. Morris MJ, **Divgi CR**, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn RD, O'Donoghue JA, Livingston P, Larson SM, Scher HI. Pilot trial of an unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. **Clin Cancer Res** 2005; 11: 7454-7461.
67. Back T, Andersson H, **Divgi CR**, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo. **J Nucl Med** 2005; 46: 2061-2067.
68. \* Pandit-Taskar N, Dauer LT, Montgomery L, St. Germain J, Zanzonico PB, **Divgi, CR**. Organ and fetal absorbed dose estimates from 99m Tc-sulfur colloid Lymphoscintigraphy and sentinel node localization in breast cancer patients. **J Nucl Med** 2006; 47(7):1202-1208.
69. \* Dauer LT, St Germain J, Williamson MJ, Zanzonico P, Modak S, Cheung NK, **Divgi C**. Whole-body clearance kinetics and external dosimetry of 131I-3F8 monoclonal antibody for radioimmunotherapy of neuroblastoma. **Health Phys** 2007;92(1):33-39.
70. \***Divgi CR**, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gönen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. **Lancet Onc** 2007; 8(4):304-310
71. Oosterwijk E, **Divgi C**, Bander NH. Related Articles, Links Active and passive immunotherapy: vaccines and antibodies. **BJU Int** 2007; 99(6):1301-1304.
72. Morris MJ, Pandit-Taskar N, **Divgi CR**, Bender S, O'donoghue JA, Nacca A, Smith-Jones P, Schwartz L, Slovin S, Finn R, Larson S, Scher HI. Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors. **Clin Cancer Res**. 2007; 13(9):2707-2713.
73. Bernal P, Raoul JL, Vidmar G, Sereegotov E, Sundram FX, Kumar A, Jeong JM, Pusuwan P, **Divgi C**, Zanzonico P, Stare J, Buscombe J, Thi Minh CT, Saw MM, Chen S, Ogbac R, Padhy AK. Intra-Arterial Rhenium-188 Lipiodol in the Treatment of Inoperable Hepatocellular Carcinoma: Results of an Iaea-Sponsored Multination Study. **Int J Radiat Oncol Biol Phys**. 2007; 69(5):1448-1455

74. Iwamoto FM, Schwartz J, Pandit-Taskar N, Peak S, **Divgi CR**, Zelenetz AD, Humm J, Abrey LE. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. **Cancer**. 2007; 110(11):2528-2534
75. \* Krug LM, Milton DT, Jungbluth AA, Chen LC, Quaia E, Pandit-Taskar N, Nagel A, Jones J, Kris MG, Finn R, Smith-Jones P, Scott AM, Old L, **Divgi C**. Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels. **J Thorac Oncol**. 2007; 2(10):947-952.
76. Hardy OT, Hernandez-Pampaloni M, Saffer JR, Scheuermann JS, Ernst LM, Freifelder R, Zhuang H, Macmullen C, Becker S, Adzick NS, **Divgi C**, Alavi A, Stanley CA. Accuracy of [18F]-Fluorodopa PET for Diagnosing and Localizing Focal Congenital Hyperinsulinism. **J Clin Endocrinol Metab**. 2007; 92(12):4706-4711
77. Schultz MK, Cessna JT, Anderson TL, Ponto JA, Petry N, Kowalsky RJ, Palmer MR, Beinlich UF, Baker W, Hinkle GH, Hung JC, Quinton T, Rice PA, **Divgi C**, Norenberg JP. A performance evaluation of (90)Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States. **Appl Radiat Isot**. 2008; 66(2):252-260
78. \* Zanzonico PB, **Divgi C**. Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery rhenium-188 lipiodol. **Semin Nucl Med**. 2008; 38(2):S30-S39.
79. Bernal P, Raoul JL, Stare J, Sereegotov E, Sundram FX, Kumar A, Jeong JM, Pusuwan P, **Divgi C**, Zanzonico P, Vidmar G, Buscombe J, Chau TT, Saw MM, Chen S, Ogbac R, Dondi M, Padhy AK. International Atomic Energy Agency-sponsored multinational study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. **Semin Nucl Med**. 2008; 38(2):S40-S45.
80. \* Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, **Divgi CR**. Antibody mass escalation study in patients with castration resistant prostate cancer using 111I-J591: Lesion detectability and dosimetric projections for 90Y radioimmunotherapy. **JNM** 2008; 49(7):1066-1074.
81. \* Quaia E, Krug LM, Pandit-Taskar N, Nagel A, Reuter VE, Humm J, **Divgi C**. The value of gamma camera and computed tomography data set coregistration to assess Lewis Y antigen targeting in small cell lung cancer by (111)Indium-labeled humanized monoclonal antibody 3S193. **Eur J Radiol**. 2008; 67(2) :292-299
82. \* Newberg AB, Ray R, Scheuermann J, Wintering N, Saffer J, SchmitzA, Freifelder R, Karp J, Lerman C, **Divgi C**. Dosimetry of 11C-carfentanil, a microopioid receptor imaging agent. **Nucl Med Commun**. 2009;30 (4):314-318

83. Morris MJ, Pandit-Taskar N, Carrasquillo J, **Divgi CR**, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. **J Clin Oncol.** 2009;27 (15):2436-2442.
84. Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wuest T, Stenner F, Perani A, Cohen L, Knuth A, **Divgi C**, Jager D, Scott AM, Ritter G, Old LJ, Renner C. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. **Int. J Cancer,** 2009;125(1):115-123
85. Andersson H, Cederkrantz E, Bäck T, **Divgi C**, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')<sub>2</sub>--a phase I study. **J Nucl Med.** 2009; 50(7):1153-1160.
86. Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, **Divgi C**, Grewal RK. Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results. **Clin Breast Cancer.** 2010;10(1):33-39.
87. Koch CJ, Scheuermann JS, **Divgi C**, Judy KD, Kachur AV, Freifelder R, Reddin JS, Karp J, Stubbs JB, Hahn SM, Driesbaugh J, Smith D, Prendergast S, Evans SM. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma. **Eur J Nucl Med Mol Imaging.** 2010; 37(11):2048-2059.
88. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, **Divgi CR**, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. Sequential Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia. **Clin Cancer Res.** 2010; 16(21): 5303-5311

#### Case Reports:

1. \* Imbriaco M, Yeung H, Narayanan G, **Divgi CR**. Prostate cancer with leg pain. **J Nucl Med.** 1998; 39: 5A, 932.

#### Reviews:

1. **Divgi CR**, Larson SM. Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. **Semin Nucl Med.** 1989; 19: 252-61.
2. Kramer EL, **Divgi CR**. Pulmonary applications of nuclear medicine. **Clin Chest Med** 1991; 12:55-75.

3. Zeng Z, **Divgi CR**, Cohen AM. Radioimmunodetection of colorectal cancer. **Perspectives in Colon and Rectal Surgery** 1991; 4:35-67.
4. Finn RD, Cheung NKV, **Divgi CR**, St. Germain J, Graham MC, Pentlow K, Larson SM. Technical challenges associated with the radiolabeling of monoclonal antibodies utilizing short-lived, positron-emitting radionuclides. **Nucl Med Biol** 1991; 18:9-13.
5. Larson SM, Macapinlac HA, Scott AM, **Divgi CR**. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. **Acta Oncol** 1993; 32 (7-8):709-715
6. Larson SM, **Divgi CR**, Scott AM. Overview of clinical radioimmunodetection of human tumors. **Cancer** 1994; 73(suppl): 832-835.
7. Scott AM, Macapinlac H, Zhang J, Kalaigian H, Graham MC, **Divgi CR**, Sgouros G, Goldsmith SJ, Larson SM. Clinical applications of fusion imaging in oncology. **Nucl Med Biol** 1994; 21:775-784.
8. Larson SM, **Divgi CR**, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D, Cheung NKV, Schlom J, Finn RD. Current status of radioimmunotherapy. **Nucl Med Biol** 1994; 21:785-792.
9. Larson SM, **Divgi CR**, Scott A, Daghigian F, Macapinlac H, Welt S. Current status of radioimmunodetection. **Nucl Med Biol** 1994; 21:721-729.
10. **Divgi CR**. Radiolabeled Mab imaging in oncology. **Contemp Oncol** 1994; 4: 56-58.
11. **Divgi CR**. Radiolabeled monoclonal antibody imaging in cancer. **Clinical Immunotherapeutics** 1995; 3(3): 218-226.
12. **Divgi CR**. Status of radiolabeled monoclonal antibodies for diagnosis and therapy of cancer. **Oncology (Huntingt)**. 1996; 10: 939-953
13. Berg WJ, **Divgi CR**, Nanus DM, Motzer RJ. Novel investigative approaches for advanced renal cell carcinoma. **Semin Oncol** 2000; 27: 234-239.
14. Oosterwijk E, **Divgi CR**, Brouwers A, Boerman OC, Larson SM, Mulders P, Old LJ. Monoclonal antibody-based therapy for renal cell carcinoma. **Urol Clin North Am**. 2003; 30: 623-631.
15. Oosterwijk E, Brouwers A, Boerman OC, Larson SM, Old LJ, Mulders P, **Divgi CR**. Monoclonal antibody therapy of kidney cancer. **Cancer Treat Res** 2003; 116: 199-212.

16. Pandit-Taskar N, Hamlin PA, Reyes S, Larson SM, **Divgi CR**. New strategies in radioimmunotherapy for lymphoma. **Curr Oncol Rep**. 2003; 5:364-371
17. Morris MJ, Pandit-Taskar N, **Divgi CR**, Larson S, Scher HI. Targeting Osseous Metastases: Rationale and Development of Radio- immunotherapy for Prostate Cancer. **Curr Oncol Rep**. 2004; 6: 222-229.
18. Pandit-Taskar N, Batraki M, **Divgi CR**. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. **J Nucl Med**. 2004; 45: 1358-1365.
19. Morris MJ, Pandit-Taskar N, **Divgi CR**, Larson SM, Scher HI. Targeting osseous metastases: Rationale and development of radioimmunotherapy for prostate cancer. **Curr Urol Rep**. 2005 ;6 (3):163-170
20. **Divgi CR**. Imaging: Staging and evaluation of lymphoma using nuclear medicine. **Semin Oncol**. 2005; 32:S11-S18
21. Jhanwar YS, **Divgi CR**. Current status of therapy of solid tumors. **J Nucl Med**. 2005; 46:1:141s-150s.
22. Morris MJ, Pandit-Taskar N, **Divgi C**, Larson S, Scher HI. Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. **Curr Urol Rep** 2005; 6: 163-170.
23. Kaufman HL, **Divgi CR**. Optimizing prostate cancer treatment by combining local radiation therapy with systemic vaccination. **Clin Cancer Res** 2005; 11: 6757-6762.
24. Oosterwijk E, **Divgi C**, Bander NH. Active and passive immunotherapy: vaccines and antibodies. **BJU Int**. 2007; 99(5 Pt B):1301-1304.
25. Divgi C. The use of positron-emission tomography in the diagnosis of tumour phenotype. **BJU Int**. 2008 Jun;101 Suppl 4:36-38.
26. Griggs WS, **Divgi C**. Radioiodine imaging and treatment in thyroid disorders. **Neuroimaging Clin N Am**. 2008 Aug;18(3):505-515, viii.
27. Perini R, Pryma D, Divgi C. Molecular imaging of renal cell carcinoma. **Urol Clin North Am**. 2008 Nov;35(4):605-611;vi.
28. R. Perini, D. Sehgal, **Divgi CR**, R. Choe, A.G. Yodh, M.A. Rosen. Non-invasive assessment of tumor neovasculature. **Cancer Metastasis Rev**. 2008 Dec;27(4):615-630.
29. **Divgi CR**. Molecular imaging of pulmonary cancer and inflammation. **Proc Am Thorac Soc**. 2009 Aug 15;6(5):464-468.

Chapters:

1. **Divgi CR**, Larson SM. Monoclonal Antibodies in the Therapy of Colorectal Cancer. *In: Cancer of the Colon, Rectum, and Anus*, Ed: Cohen AM, Winawer SJ. McGraw-Hill Inc, New York 1995.
2. **Divgi CR**. Radioimmunotherapy in hematologic and solid malignancies. *In: Cancer Immunotherapy*, Ed: Michiels L, Motmans K. Human Press, Inc., Totowa, NJ, 2000.
3. Oosterwijk E, **Divgi CR**, Steffens M, Bander N. Monoclonal Antibodies in Advanced Renal Cell Carcinoma. *In: Current Clinical Urology: Renal Cell Carcinoma: Molecular Biology, Immunology and Clinical Management*. Ed: Bukowski RM, Novick A. Humana Press Inc., Totowa, NJ, 2000.
4. **Divgi CR**, Oosterwijk E, Bander NH, Welt S, Larson SM, Old LJ. Development of anti-renal carcinoma antibody G250. *In: Nuclear Oncology*. Ed: Khalkhali I, Maublant J, Goldsmith SJ. Lippincott Williams and Wilkins, New York, 2000.
5. **Divgi CR**. Radiolabeled Monoclonal Antibodies in Tumor Therapy *In: Nuclear Oncology*. Ed: Khalkhali I, Maublant J, Goldsmith SJ. Lippincott Williams and Wilkins, New York, 2000.
6. Larson SM, **Divgi CR**, Sgouros G, Cheung V, Nai-Kong, Scheinberg DA. Radioisotope Conjugates. *In: Principals and Practice of the Biologic Therapy of Cancer, 3rd Edition*, pp 396-14.3. Lippincott Williams & Wilkins, Philadelphia, PA, 2000
7. **Divgi CR**, Larson SM. Nuclear Medicine. *In: Manual of Clinical Oncology, 4th Edition*. Ed: Casciato DA, Lowitz BB. Lippincott Williams & Wilkins, Philadelphia, PA, 2000.
8. **Divgi CR**, Oosterwijk E, Steffens M, Bander N. Monoclonal antibodies to renal cancer antigens *In: Renal & Adrenal Tumors*. Oxford University Press Inc., New York, 2003
9. **Divgi CR**, Larson SM. PET in genitourinary tumors: prostate, bladder testicular and renal cancer. *In: Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd Edition*. Ed: Ell PJ, Gambhir S. Churchill Livingstone, Edinburgh, 2004.
10. **Divgi CR**, Larson SM. Nuclear Medicine. *In: Manual of Clinical Oncology, 5th Edition*. Ed: Casciato DA. Lippincott Williams & Wilkins, Philadelphia, PA, 2004.
11. Chang DZ, Sabbatini P, **Divgi C**, Livingston PO, Houghton A. Immunotherapy of gynecologic malignancies. *In: Principles and Practice of Gynecologic Oncology, 4th Edition*. Ed: Hoskins WJ, Young RC, Markman M. Lippincott Williams & Wilkins, Philadelphia, PA, 2005.

12. Pandit-Taskar N, **Divgi CR**. Functional and Molecular Imaging of Prostate Cancer. *In: Molecular Oncology of Prostate Cancer. Ed: Ross JS, Foster CS. Jones & Bartlett Publishers, Boston, MA, 2006.*
13. Pandit-Taskar N, **Divgi CR**. Radioimmunotherapy: Current Status and Future Directions. *In: Therapeutic Monoclonal Antibodies: From Bench to Clinic. Ed: An Z. John Wileys & Sons, Inc, 2009.*
14. **Divgi CR**. Nuclear Medicine. *In: Manual of Clinical Oncology, 6th Edition. Ed: Casciato DA, Territo MC. Lippincott Williams & Wilkins, Philadelphia, PA, 2009.*

Editorials:

1. **Divgi CR**, AM Cohen. Commentary: radiolabeled antibody imaging in the management of colorectal cancer. **Colon and Rectal Surgery Outlook** 1991; 4:2-3.
2. **Divgi CR**. All of the Above (With Caveats for Each) [Editorial]. **J Nucl Med** 1998; 39: 42-43.
3. Lovqvist A, **Divgi CR**. Bullets to magic bullets--and miles to go before we sleep. **J Nucl Med**. 1998; 39: 1776-7.
4. **Divgi CR**, Pandit-Taskar N. PET: too much of a good thing? Does the plethora of choices impact on patient management? **Eur J Nucl Med Mol Imaging**. 2005; 32:398.
5. **Divgi C**. Editorial: what ails solid tumor radioimmunotherapy? **Cancer Biother Radiopharm**. 2006; 21: 81-84.
6. **Divgi C**. Instant gratification must wait. **Eur J Nucl Med Mol Imaging**. 2006; 33:979-80
7. McEwan AJ, Van Brocklin HF, **Divgi C**. Action plan for emerging molecular imaging technologies. **J Nucl Med**. 2008 Feb;49(2):37N-40N.
8. **Divgi C**. The promise of locoregional radiopharmaceutical therapy: will it ever be realized? **J Nucl Med**. 2008 Mar;49(3):340
9. Pryma D., **Divgi CR**, Meta-iodobenzyl guanidine for detection and staging of neuroendocrine tumors". *Journal: Nuclear Medicine & Biology, Vol. 35, (S1) Issue Supplement 1, 2008, page S3-S8*
10. **Divgi CR**. Molecular imaging of pulmonary cancer and inflammation. *Proc Am Thorac Soc*. 2009 Aug 15;6(5):464-468

This is to acknowledge the receipt of your (C) letter/application dated

10/7/2011, and to inform you that the initial processing which includes an administrative review has been performed.

Notification (31-28713-01)  
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 576189.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.